Opus Genetics to Participate in Leading Medical Conferences in May 2026 [Yahoo! Finance]
Opus Genetics, Inc. (IRD)
Company Research
Source: Yahoo! Finance
the “Company”), a clinical-stage biopharmaceutical company developing gene therapies to restore vision and prevent blindness in patients with inherited retinal diseases (IRDs), today announced that members of its leadership team will participate in several leading ophthalmology and industry conferences. “We look forward to sharing progress across our programs at ARVO and other leading meetings this May, including encouraging findings from our LCA5 and BEST1 gene therapy programs,” said Dr. George Magrath, Chief Executive Officer, Opus Genetics. “At ARVO, we will present previously disclosed preliminary data from our ongoing Phase 1b/2a OPGx-BEST1 study, alongside new preclinical and translational work advancing our pipeline. These meetings provide an important opportunity to engage with the ophthalmology community as we work to develop durable, one-time treatments for inherited retinal diseases.” Retinal Therapeutics Innovation Summit 2026 Presentation Title: Safety and Efficacy
Show less
Read more
Impact Snapshot
Event Time:
IRD
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
IRD alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
IRD alerts
High impacting Opus Genetics, Inc. news events
Weekly update
A roundup of the hottest topics
IRD
News
- Opus Genetics to Participate in Leading Medical Conferences in May 2026GlobeNewswire
- Opus Genetics Announces Data Presentations at the 2026 American Society of Cataract and Refractive Surgery Annual MeetingGlobeNewswire
- Opus Genetics Solidifies Leadership Position in Gene Therapy Development for Inherited Retinal Diseases with Strategic Long-Term Financing by Oberland Capital [Yahoo! Finance]Yahoo! Finance
- Opus Genetics Solidifies Leadership Position in Gene Therapy Development for Inherited Retinal Diseases with Strategic Long-Term Financing by Oberland CapitalGlobeNewswire
- Opus Genetics (IRD) is now covered by Cantor Fitzgerald. They set an "overweight" rating and a $15.00 price target on the stock.MarketBeat
IRD
Sec Filings
- 4/27/26 - Form 4
- 4/27/26 - Form 4
- 4/27/26 - Form 4
- IRD's page on the SEC website